Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04707534 · ClinicalTrials.gov registry record · Phase 4

Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19

A Phase 4 study of Covid19, sponsored by University of Oklahoma.

Completed
Registry status
Phase 4
Development phase
110
Enrollment target
1
Study location

NCT04707534 is a Phase 4 study of Covid19 that has completed, run by University of Oklahoma. The registered enrollment target is 110 participants, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04707534, a Phase 4 study of Covid19, has completed, sponsored by University of Oklahoma.

COMPLETED
Registry status
Phase 4
Development phase
110 participants
Enrollment target
1
Study location

Study Summary

This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.

Conditions Studied

Interventions

  • DRUG Dexamethasone

Study Locations (1)

Oklahoma

  • University of Oklahoma Medical Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2021-01-21
Est. Completion 2022-03-04
Phase Phase 4

Sponsor

University of Oklahoma

358 total trials

What the Registry Record Tells You About NCT04707534

The ClinicalTrials.gov registry entry for NCT04707534 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (96% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 1 intervention - of which Dexamethasone is the first listed.

NCT04707534 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT04707534 about?

NCT04707534 is a clinical study titled "Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19". This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.

What is the current status of trial NCT04707534?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2021-01-21. Estimated completion is 2022-03-04.

What conditions does trial NCT04707534 study?

This clinical trial studies the following conditions: Covid19.

What interventions are being tested in trial NCT04707534?

The interventions under investigation include: Dexamethasone (DRUG).

Who is sponsoring clinical trial NCT04707534?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04707534 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Covid19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.